Top Markets
#1 EXOD EXOD +56.80%
#2 Glidr Glidr +33.64%
#3 Cysic Cysic +24.17%
#4 Nockchain Nockchain +18.65%
#5 Velvet Velvet +18.00%
#6 Nillion Nillion +13.02%
#7 FOLKS FOLKS +12.57%
#8 Versatize Coin Versatize Coin +12.49%
#9 Humanity Humanity +11.40%
#10 Bedrock Bedrock +10.87%
Coin of the day
EXOD EXOD
Impostazioni
Lingua
ITALIANO
Valuta
USD
Tema
Sorrento Therapeutics, Inc. Sorrento Therapeutics, Inc.

Sorrento Therapeutics, Inc.

0L85
Classifica tra le azioni #37352
Sorrento Therapeutics, Inc. is a biopharmaceutical firm, active in both... Sorrento Therapeutics, Inc. is a biopharmaceutical firm, active in both clinical development and commercialization, dedicated to creating treatments across a broad spectrum of illnesses, including cancer, autoimmune conditions, inflammatory disorders, viral infections, and neurodegenerative diseases. The company conducts its operations through two distinct divisions: Sorrento Therapeutics and Scilex. For cancer treatment, Sorrento employs its unique G-MAB antibody library alongside sophisticated targeted delivery methods. These include chimeric and dimeric antigen receptor T-cell (CAR-T) therapies, antibody-drug conjugates, and bispecific antibody strategies. Additionally, its Sofusa drug delivery system enables the direct administration of biologics into the lymphatic system. Sorrento's pipeline features several clinical-stage programs. These encompass an anti-CD38 CAR-T therapy targeting multiple myeloma, amyloidosis, and graft-versus-host disease. The company is also advancing resiniferatoxin, a non-opioid TRPV1 agonist neurotoxin, for managing pain associated with late-stage cancer and osteoarthritis of the knee. Furthermore, ZTlido, a lidocaine delivery system, addresses postherpetic neuralgia. In the realm of pain management, SEMDEXA, an injectable viscous gel, is undergoing Phase III trials for sciatica (a form of lower back pain); SP-103, an experimental non-aqueous lidocaine topical system, is being developed for chronic low back pain; and SP-104 is a novel, low-dose, delayed-release naltrexone hydrochloride formulation for fibromyalgia. The company maintains several strategic collaborations, including a partnership with SmartPharm Therapeutics Inc. for a gene-encoded antibody vaccine against COVID-19, and with Celularity, Inc. for a Phase I/II clinical trial involving up to 94 COVID-19 patients. Additionally, Sorrento works with Mount Sinai Health System on COVI-SHIELD, an antibody treatment for SARS-CoV-2 infection, and with Mayo Clinic on a Phase Ib pilot study utilizing Sofusa technology for Ipilimumab delivery in melanoma patients. Established in 2006, Sorrento Therapeutics operates from its headquarters in San Diego, California.
Prezzo delle azioni
$0.0033
Ultima sincronizzazione: 2026-02-26
Capitalizzazione di mercato
$1.79M
Variazione (1 giorno)
-21.43%
Variazione (1 anno)
371.43%
Paese
US
Scambia Sorrento Therapeutics, Inc. (0L85)

Categoria

Healthcare
Storico del prezzo dell'azione per Sorrento Therapeutics, Inc. (0L85)
Prezzo di chiusura più alto: $0.00 il 2026-02-01

Prezzo di chiusura più basso: $7.66 il 2018-01-01
Storico del prezzo dell'azione di Sorrento Therapeutics, Inc. dal 2018 al 2026
Andamento annuale del prezzo dell'azione
Anno Performance
2026 (TTM) -55.40%
2025 408.33%
2024 -97.87%
2023 -94.47%
2022 -81.87%
2021 -25.41%
2020 116.28%
2019 1.65%
2018 0.00%
Prezzo dell'azione per aziende simili o concorrenti
Azienda Prezzo dell'azione Variazione 1a% Il paese
Royalty Pharma plc Royalty Pharma plc
Royalty Pharma plc
RPRX.US
 $58.56 61.10%
US
Swedish Orphan Biovitrum AB Swedish Orphan Biovitrum AB
Swedish Orphan Biovitrum AB
SOBI.ST
 $49.19 71.73%
SE
Ipsen S.A. Ipsen S.A.
Ipsen S.A.
IPN.PA
 $185.04 40.51%
FR
Recordati Industria Chimica e Farmaceutica S.p.A. Recordati Industria Chimica e Farmaceutica S.p.A.
Recordati Industria Chimica e Farmaceutica S.p.A.
REC.MI
 $62.27 4.40%
IT
Corcept Therapeutics Incorporated Corcept Therapeutics Incorporated
Corcept Therapeutics Incorporated
CORT.US
 $114.37 59.39%
US